|
|
AcelRx Announces Positive Phase 2 Results From A Study Of ARX-01 Sufentanil NanoTabs In Treating Post-Operative Pain
|
|
AcelRx Pharmaceuticals, Inc. announced positive results from the second Phase 2 clinical study evaluating the safety and efficacy of its ARX-01 Sufentanil NanoTabs(TM) for the management of acute post-operative pain in patients requiring opioid analgesia during hospitalization. Compared to placebo, patients receiving ARX-01 Sufentanil NanoTabs for management of post-operative pain following major abdominal surgery reported statistically significant reductions in pain intensity over the 12-hour study period. |
|
| |
|
AlphaRx And Gaia BioPharma Report Positive Efficacy Results In A Pre-Clinical Trial Of GAI-122 Injectable Nano-emulsion For Post-operative Delirium
|
|
AlphaRx Inc. (OTCBB: ALRX) and Gaia BioPharma Limited reported positive pre-clinical results on GAI-122 injectable nanoemulsion in multiple in vitro and in vivo studies of memory impairment after prolonged anesthesia. |
|
| |
|
Neupro(R) (rotigotine Transdermal Patch) Can Now Be Prescribed To All Patients With Idiopathic Parkinson's Disease In Europe
|
|
UCB announced that Neupro(R) (rotigotine transdermal patch) can now be prescribed to all patients with idiopathic Parkinson's disease in Europe and is newly available for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (RLS) in adults. This follows the decision of the European Commission to lift treatment restrictions on Neupro® in line with the recommendation of the European Medicines Agency (EMEA), issued on 29 May 2009. |
|
| |
|
European Medicines Agency Recommends Withdrawal Of Dextropropoxyphene-Containing Medicines (Including Co-Proxamol)
|
|
The European Medicines Agency (EMEA) has today announced their recommendation to withdraw the marketing authorisations for dextropropoxyphene-containing medicines (including co-proxamol) across the European Union (EU). This recommendation was made after the Committee on Medicinal Products for Human Use (CHMP) concluded that the risks, particularly of potentially fatal overdose, were greater than the medicine's benefits. The EMEA's recommendation has been forwarded to the European Commission (EC) for a decision which will be legally binding across the EU. In the UK, the only medicine affected by the EMEA's announcement is co-proxamol. |
|
| |
|
Tapentadol Tablets For Moderate To Scute Pain In Over 18s Now Available For Use In The United States
|
|
German pain expert company Grünenthal GmbH announces that the new centrally acting analgesic tapentadol is now available in the United States. The drug is indicated for the relief of moderate to severe acute pain in patients 18 years of age and older. Approval was given by the US Food and Drug Administration (FDA) in November 2008 for tapentadol (NUCYNTATM) tablets. With the cooperation of Grünenthal and its marketing partner Ortho-McNeil-Janssen Pharmaceuticals, Inc., the medication can now be prescribed by physicians and other appropriate health care professionals in the United States. |
|
| |
|
Antidepressant Directly Stimulates Brain Growth Factor Receptors
|
|
The widely used antidepressant and pain medication amitriptyline--but not other closely related drugs -- can impersonate the brain's own growth factors, researchers at Emory University School of Medicine have shown. |
|
| |
|
Gold Treatment Relieves Pain
|
|
Many animals and people experience chronic joint pain. In dogs, a common source of joint pain is hip dysplasia, a developmental defect of the hip joint. Implantation of gold into the soft tissues around the hip joints of dogs with dysplasia can relieve pain and lessen stiffness for several years. |
|
| |
|
What Is Lyrica (pregabalin)? What Does Lyrica Treat?
|
|
Lyrica is Pfizer's trade name for a drug called pregabalin. Pregabalin is an anticonvulsant (anti-seizure) drug that is often used to treat neuropathic pain as well as partial seizures that are common in temporal lobe epilepsy. In Europe, pregabalin is also approved to treat generalized anxiety disorder. |
|
| |
